Not a good buy right now for an impatient buyer: no proprietary buy signals, weakening profitability, and only mixed technicals.
Price is in the middle of a pivot-to-resistance zone (above ~71.6 pivot, below ~75.6 R1), which limits immediate upside while downside risk remains.
Options positioning (OI skew to calls) is mildly bullish, but trading activity is extremely thin, so sentiment signal is weak.
With earnings coming (2026-02-17) and margins collapsing in the latest quarter, the near-term risk/reward does not justify chasing at ~73.36 pre-market.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.578) but contracting → downside momentum is easing, not reversing.
RSI (6): 64.61 (neutral-to-slightly warm) → not oversold; limited “bounce” edge for an impatient entry.
Moving averages: converging → consolidation/indecision, no clear trending setup.
Key levels: Pivot 71.588 (near-term support), R1 75.645 (near-term resistance). At 73.36, upside to R1 is ~3.1% while a drop back to pivot is ~-2.4%.
Pattern-based odds: model implies a modest bearish drift (next day -0.84%, next month -1.1% expected).
Cons: Lowered target below current pre-market (~73.36) implies limited upside and/or overvaluation versus their expectations; cautious 2026 outlook.
Wall Street analysts forecast BXC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BXC is 71.5 USD with a low forecast of 68 USD and a high forecast of 75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BXC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BXC is 71.5 USD with a low forecast of 68 USD and a high forecast of 75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 76.550
Low
68
Averages
71.5
High
75
Current: 76.550
Low
68
Averages
71.5
High
75
DA Davidson
Neutral
downgrade
$75 -> $68
AI Analysis
2025-11-06
Reason
DA Davidson
Price Target
$75 -> $68
AI Analysis
2025-11-06
downgrade
Neutral
Reason
DA Davidson lowered the firm's price target on BlueLinx to $68 from $75 and keeps a Neutral rating on the shares. The company's Q3 results were highlighted by encouraging Specialty volumes growth and flat pricing, though the firm is taking a more conservative stance around the 2026 demand environment and commodity pricing assumptions, the analyst tells investors in a research note.
DA Davidson
Neutral
downgrade
$80 -> $75
2025-08-04
Reason
DA Davidson
Price Target
$80 -> $75
2025-08-04
downgrade
Neutral
Reason
DA Davidson lowered the firm's price target on BlueLinx to $75 from $80 and keeps a Neutral rating on the shares. The stock traded modestly lower since reporting Q2 results despite a better than feared performance in a tough environment, the analyst tells investors in a research note. The silver linings for BlueLinx included y/y volume gains in both segments, fueled in part by execution within multi-family, as well as a relatively stable gross margin performance in Specialty Products, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BXC
